Table 3 Estimated subdistribution hazard ratios for temporal lobe injury (TLI) using univariate and multivariate competing risk regression models
Variable | Univariate analyses | Multivariate analyses | ||
|---|---|---|---|---|
sHRa (95% CI) | P value | sHRa (95% CI) | P value | |
N-classification | ||||
 N2–3 vs N0–1 | 1.330 (0.853–2.070) | 0.210 |  |  |
AJCC 2010 stage | ||||
 IVB vs IVA | 0.806 (0.265–2.450) | 0.700 |  |  |
Chemotherapy | ||||
 Induction (vs no) | 2.270 (0.794–6.480) | 0.130 |  |  |
 Concurrent (vs no) | 0.744 (0.445–1.240) | 0.260 |  |  |
 Adjuvant (vs no) | 1.080 (0.618–1.890) | 0.790 |  |  |
 Concurrent cetuximab or nimotuzumab (vs no) | 1.760 (0.803–3.850) | 0.160 |  |  |
 Nasopharynx boost (vs no) | 2.430 (0.919–6.440) | 0.074 |  |  |
Overall treatment time (OTT) | ||||
 > 45 vs ≤45 | 0.941 (0.567–1.560) | 0.810 |  |  |
 Temporal lobe Dmax (per Gy increase) | 1.260 (1.150–1.370) | < 0.001 |  |  |
 Temporal lobe D1cc (per Gy increase) | 1.270 (1.180–1.370) | < 0.001 | 1.500 (1.212–1.856) | < 0.001 |
 Temporal lobe V20 (per cc increase) | 1.040 (1.030–1.060) | < 0.001 | 1.072 (1.009–1.139) | 0.024 |
 Temporal lobe V30 (per cc increase) | 1.060 (1.040–1.090) | < 0.001 |  |  |
 Temporal lobe V40 (per cc increase) | 1.100 (1.070–1.120) | < 0.001 |  |  |
 Temporal lobe V50 (per cc increase) | 1.130 (1.090–1.170) | < 0.001 |  |  |
 Temporal lobe V60 (per cc increase) | 1.190 (1.130–1.250) | < 0.001 |  |  |
 Temporal lobe V70 (per cc increase) | 1.380 (1.260–1.510) | < 0.001 |  |  |